Eric Ehrke-Schulz

Years Active: 2020-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Erwan Sallard, Lukas Schulte, Alexander van den Boom, Alexander Klimovitskii, Julius Knierer, Claudia Hagedorn, Maximilian Knocks, Wenli Zhang, Florian Kreppel, Anja Ehrhardt, Eric Ehrke-Schulz
Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5. The journal of gene medicine (2023)
Sebastian Schellhorn, Dominik Brücher, Natascha A Wolff, Katrin Schröer, Erwan Sallard, Kemal Mese, Wenli Zhang, Eric Ehrke-Schulz, Frank Thévenod, Andreas Plückthun, Anja Ehrhardt
Targeting Oncolytic Adenoviruses to Cancer Cells Using a Designed Ankyrin Repeat Protein Lipocalin-2 Fusion Protein. Human gene therapy 34 (5-6) (2023)
Johannes Doerner, Erwan Sallard, Wenli Zhang, Manish Solanki, Jing Liu, Eric Ehrke-Schulz, Hubert Zirngibl, André Lieber, Anja Ehrhardt
Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo. Molecular cancer therapeutics 21 (3) (2022)
Anouk Willemsen, Alexander van den Boom, Julienne Dietz, Seval Bilge Dagalp, Firat Dogan, Ignacio G Bravo, Anja Ehrhardt, Eric Ehrke-Schulz
Genomic and phylogenetic characterization of ChPV2, a novel goat PV closely related to the Xi-PV1 species infecting bovines. Virology journal 17 (1) (2020)

Eric Ehrke-Schulz.css-eqlu8i{font-size:small;padding-left:4px;}